Patient exposure
DISEASE, ADVERSE EVENT
Figure Patients were monitored for the occurrence of DLTs for 28 days after the first dose of SQZ-PBMC-HPV. Administration in subsequent cohorts did not begin until the Study Safety Committee had reviewed the available safety data and determined that dose escalation was warranted. All patients in the safety population were DLT evaluable. The median number of doses administered was 4 (range 2, 10). Five patients completed the treatment when their supply of autologous product was exhausted; nine patients discontinued treatment due to progressive disease; one patient died while on treatment due to an unrelated adverse event and one patient withdrew consent. Supplementary Table 